KYAN Therapeutics
Singapore, Singapore· Est.
AI‑driven functional assay that predicts personalized cancer treatment combos from limited tumor tissue.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑driven functional assay that predicts personalized cancer treatment combos from limited tumor tissue.
Oncology
Technology Platform
Optim.AI™ combines live‑cell drug‑sensitivity assays with Small‑Data AI to predict patient‑specific responses to single agents and multi‑drug combinations across a >100‑drug inventory.
Opportunities
Expansion into immunotherapy combinations, partnerships with pharma for trial enrichment, and regulatory clearance for broader market adoption.
Risk Factors
Dependence on viable tumor tissue, regulatory hurdles for diagnostic clearance, and competition from other functional profiling platforms.
Competitive Landscape
Competes with genomic profiling and other ex‑vivo drug‑response assays; differentiates through AI‑driven combinatorial prediction and rapid turnaround.